Skip to main content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
J Clin Invest. 1997 Dec 1; 100(11): 2744–2751.
doi: 10.1172/JCI119820
PMCID: PMC508478
PMID: 9389738

Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice.

H Wennbo, M Gebre-Medhin, A Gritli-Linde, C Ohlsson, O G Isaksson, and J Törnell
Author information Copyright and License information PMC Disclaimer

Abstract

Transgenic mice overexpressing the human growth hormone gene develop mammary carcinomas. Since human growth hormone gene can activate both the growth hormone receptor (GHR) and the prolactin (PRL) receptor (PRLR), it is not clear which receptor system is responsible for the malignant transformation. To clarify the receptor specificity, we created transgenic mice with two different genes: (a) transgenic mice overexpressing the bovine growth hormone (bGH) gene having high levels of bGH only activating the GHR and also high serum levels of IGF-I; and (b) transgenic mice overexpressing the rat PRL (rPRL) gene that have elevated levels of PRL (one line 150 ng/ml and one line 13 ng/ml) only binding to the PRLR and with normal IGF-I levels. When analyzed histologically, all of the PRL transgenic female mice developed mammary carcinomas at 11-15 mo of age. Only normal mammary tissue was observed among the bGH transgenic animals and the controls. Cell lines established from a tumor produced rPRL and expressed PRLR. In organ culture experiments, an auto/paracrine effect of rPRL was demonstrated. In conclusion, activation of the PRLR is sufficient for induction of mammary carcinomas in mice, while activation of the GHR is not sufficient for mammary tumor formation.

Full Text

The Full Text of this article is available as a PDF (717K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  • Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev. 1996 Dec;17(6):639–669. [PubMed] [Google Scholar]
  • Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H, Edery M, Brousse N, Babinet C, Binart N, et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev. 1997 Jan 15;11(2):167–178. [PubMed] [Google Scholar]
  • Bonneterre J, Peyrat JP, Beuscart R, Lefebvre J, Demaille A. Prognostic significance of prolactin receptors in human breast cancer. Cancer Res. 1987 Sep 1;47(17):4724–4728. [PubMed] [Google Scholar]
  • Murphy LJ, Murphy LC, Vrhovsek E, Sutherland RL, Lazarus L. Correlation of lactogenic receptor concentration in human breast cancer with estrogen receptor concentration. Cancer Res. 1984 May;44(5):1963–1968. [PubMed] [Google Scholar]
  • Biswas R, Vonderhaar BK. Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long-term tissue culture. Cancer Res. 1987 Jul 1;47(13):3509–3514. [PubMed] [Google Scholar]
  • Manni A, Wright C, Davis G, Glenn J, Joehl R, Feil P. Promotion by prolactin of the growth of human breast neoplasms cultured in vitro in the soft agar clonogenic assay. Cancer Res. 1986 Apr;46(4 Pt 1):1669–1672. [PubMed] [Google Scholar]
  • Shiu RP. Prolactin receptors in human breast cancer cells in long-term tissue culture. Cancer Res. 1979 Nov;39(11):4381–4386. [PubMed] [Google Scholar]
  • Fuh G, Wells JA. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem. 1995 Jun 2;270(22):13133–13137. [PubMed] [Google Scholar]
  • Matsuzawa A. Hormone dependence and independence of mammary tumors in mice. Int Rev Cytol. 1986;103:303–340. [PubMed] [Google Scholar]
  • Goffin V, Shiverick KT, Kelly PA, Martial JA. Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. Endocr Rev. 1996 Aug;17(4):385–410. [PubMed] [Google Scholar]
  • Bazan JF. A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain. Biochem Biophys Res Commun. 1989 Oct 31;164(2):788–795. [PubMed] [Google Scholar]
  • Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980 Jan;12(1):71–79. [PubMed] [Google Scholar]
  • Bengtsson BA, Edén S, Ernest I, Odén A, Sjögren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223(4):327–335. [PubMed] [Google Scholar]
  • Ituarte EA, Petrini J, Hershman JM. Acromegaly and colon cancer. Ann Intern Med. 1984 Nov;101(5):627–628. [PubMed] [Google Scholar]
  • Decouvelaere C, Peyrat JP, Bonneterre J, Djiane J, Jammes H. Presence of the two growth hormone receptor messenger RNA isoforms in human breast cancer. Cell Growth Differ. 1995 Apr;6(4):477–483. [PubMed] [Google Scholar]
  • Törnell J, Rymo L, Isaksson OG. Induction of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice. Int J Cancer. 1991 Aug 19;49(1):114–117. [PubMed] [Google Scholar]
  • Bartke A, Cecim M, Tang K, Steger RW, Chandrashekar V, Turyn D. Neuroendocrine and reproductive consequences of overexpression of growth hormone in transgenic mice. Proc Soc Exp Biol Med. 1994 Sep;206(4):345–359. [PubMed] [Google Scholar]
  • Törnell J, Carlsson B, Pohjanen P, Wennbo H, Rymo L, Isaksson O. High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):237–242. [PubMed] [Google Scholar]
  • D'Ercole AJ, Stiles AD, Underwood LE. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci U S A. 1984 Feb;81(3):935–939. [PMC free article] [PubMed] [Google Scholar]
  • Mathews LS, Norstedt G, Palmiter RD. Regulation of insulin-like growth factor I gene expression by growth hormone. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9343–9347. [PMC free article] [PubMed] [Google Scholar]
  • Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol. 1989 Mar;3(3):509–517. [PubMed] [Google Scholar]
  • Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, Rosen N. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res. 1990 Jan 1;50(1):48–53. [PubMed] [Google Scholar]
  • Huff KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME, Dickson RB. Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res. 1986 Sep;46(9):4613–4619. [PubMed] [Google Scholar]
  • Karey KP, Sirbasku DA. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res. 1988 Jul 15;48(14):4083–4092. [PubMed] [Google Scholar]
  • Mathews LS, Hammer RE, Behringer RR, D'Ercole AJ, Bell GI, Brinster RL, Palmiter RD. Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology. 1988 Dec;123(6):2827–2833. [PubMed] [Google Scholar]
  • Neuenschwander S, Schwartz A, Wood TL, Roberts CT, Jr, Hennighausen L, LeRoith D. Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest. 1996 May 15;97(10):2225–2232. [PMC free article] [PubMed] [Google Scholar]
  • Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM. Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology. 1996 Jan;137(1):321–330. [PubMed] [Google Scholar]
  • Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II) Br J Cancer. 1995 Nov;72(5):1189–1193. [PMC free article] [PubMed] [Google Scholar]
  • Mathews LS, Hammer RE, Brinster RL, Palmiter RD. Expression of insulin-like growth factor I in transgenic mice with elevated levels of growth hormone is correlated with growth. Endocrinology. 1988 Jul;123(1):433–437. [PubMed] [Google Scholar]
  • Cooke NE, Baxter JD. Structural analysis of the prolactin gene suggests a separate origin for its 5' end. Nature. 1982 Jun 17;297(5867):603–606. [PubMed] [Google Scholar]
  • Palmiter RD, Brinster RL, Hammer RE, Trumbauer ME, Rosenfeld MG, Birnberg NC, Evans RM. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature. 1982 Dec 16;300(5893):611–615. [PMC free article] [PubMed] [Google Scholar]
  • Ofverstedt LG, Hammarström K, Balgobin N, Hjertén S, Pettersson U, Chattopadhyaya J. Rapid and quantitative recovery of DNA fragments from gels by displacement electrophoresis (isotachophoresis). Biochim Biophys Acta. 1984 Jun 16;782(2):120–126. [PubMed] [Google Scholar]
  • Hammer RE, Brinster RL, Palmiter RD. Use of gene transfer to increase animal growth. Cold Spring Harb Symp Quant Biol. 1985;50:379–387. [PubMed] [Google Scholar]
  • Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. [PubMed] [Google Scholar]
  • Cooke NE, Coit D, Weiner RI, Baxter JD, Martial JA. Structure of cloned DNA complementary to rat prolactin messenger RNA. J Biol Chem. 1980 Jul 10;255(13):6502–6510. [PubMed] [Google Scholar]
  • Sandstedt J, Ohlsson C, Norjavaara E, Nilsson J, Törnell J. Disproportional bone growth and reduced weight gain in gonadectomized male bovine growth hormone transgenic and normal mice. Endocrinology. 1994 Dec;135(6):2574–2580. [PubMed] [Google Scholar]
  • Sinha YN, Salocks CB, Wickes MA, Vanderlaan WP. Serum and pituitary concentrations of prolactin and growth hormone in mice during a twenty-four hour period. Endocrinology. 1977 Mar;100(3):786–791. [PubMed] [Google Scholar]
  • Huseby RA, Soares MJ, Talamantes F. Ectopic pituitary grafts in mice: hormone levels, effects on fertility, and the development of adenomyosis uteri, prolactinomas, and mammary carcinomas. Endocrinology. 1985 Apr;116(4):1440–1448. [PubMed] [Google Scholar]
  • Adler RA. The anterior pituitary-grafted rat: a valid model of chronic hyperprolactinemia. Endocr Rev. 1986 Aug;7(3):302–313. [PubMed] [Google Scholar]
  • Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res. 1995 Jun 15;55(12):2591–2595. [PubMed] [Google Scholar]
Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation
-